文献速递肝病

机器学习算法预测慢性丙型肝炎直接抗病毒治疗失败:一项HCV-TARGET分析

Machine learning algorithms for predicting direct-acting antiviral treatment failure in chronic hepatitis C: An HCV-TARGET analysis.
PubMed 文献 · Hepatology · 2022-02-03

本研究利用HCV-TARGET注册数据,纳入6525例接受全口服直接抗病毒药物治疗且具有病毒学结局的HCV感染成人,开发并验证机器学习算法预测治疗失败。验证集中梯度提升机、随机森林、前馈神经网络和弹性网的C统计量均优于多变量逻辑回归,梯度提升机在约登指数平衡阈值下敏感度66.2%、特异度65.1%。

要点

  • 梯度提升机在验证集中预测治疗失败的C统计量为0.69(95%CI 0.64-0.74)。
  • 四种机器学习算法均优于多变量逻辑回归(C统计量0.51,95%CI 0.46-0.57)。
  • 梯度提升机识别的重要预测因子包括白蛋白、肝酶、总胆红素、性别、HCV病毒载量等。

核心结论

  • 机器学习算法在直接抗病毒治疗失败的风险预测和分层方面表现有效。

研究设计与样本

  • 利用HCV-TARGET注册数据,纳入接受全口服直接抗病毒治疗且有病毒学结局的HCV感染成人,训练集4894例、验证集1631例。
  • 潜在治疗前预测变量共179个,包括社会人口学、临床特征和病毒学数据。
  • 采用多变量逻辑回归以及弹性网、随机森林、梯度提升机和前馈神经网络机器学习算法预测治疗失败。

主要发现

  • 6525例HCV感染成人中,95.3%获得持续病毒学应答,4.7%发生直接抗病毒治疗失败。
  • 验证集中各算法预测治疗失败的C统计量(95%CI):梯度提升机0.69(0.64-0.74);随机森林0.68(0.63-0.73);前馈神经网络0.66(0.60-0.71);弹性网0.64(0.59-0.70);多变量逻辑回归0.51(0.46-0.57)。
  • 使用约登指数确定平衡风险评分阈值时,梯度提升机敏感度66.2%、特异度65.1%,需评估12例个体以识别1例治疗失败。
  • 超过55%的治疗失败患者被梯度提升机归入风险最高的三个十分位亚组(阳性预测值6%-14%)。
  • 梯度提升机识别的前10位预测因子包括白蛋白、肝酶(天冬氨酸氨基转移酶、碱性磷酸酶)、总胆红素水平、性别、HCV病毒载量、钠水平、肝细胞癌、血小板水平和吸烟。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: We aimed to develop and validate machine learning algorithms to predict direct-acting antiviral (DAA) treatment failure among patients with HCV infection. APPROACH AND RESULTS: We used HCV-TARGET registry data to identify HCV-infected adults receiving all-oral DAA treatment and having virologic outcome. Potential pretreatment predictors (n = 179) included sociodemographic, clinical characteristics, and virologic data. We applied multivariable logistic regression as well as elastic net, random forest, gradient boosting machine (GBM), and feedforward neural network machine learning algorithms to predict DAA treatment failure. Training (n = 4894) and validation (n = 1631) patient samples had similar sociodemographic and clinical characteristics (mean age, 57 years; 60% male; 66% White; 36% with cirrhosis). Of 6525 HCV-infected adults, 95.3% achieved sustained virologic response, whereas 4.7% experienced DAA treatment failure. In the validation sample, machine learning approaches performed similarly in predicting DAA treatment failure (C statistic [95% CI]: GBM, 0.69 [0.64-0.74]; random forest, 0.68 [0.63-0.73]; feedforward neural network, 0.66 [0.60-0.71]; elastic net, 0.64 [0.59-0.70]), and all four outperformed multivariable logistic regression (0.51 [0.46-0.57]). Using the Youden index to identify the balanced risk score threshold, GBM had 66.2% sensitivity and 65.1% specificity, and 12 individuals were needed to evaluate to identify 1 DAA treatment failure. Over 55% of patients with treatment failure were classified by the GBM in the top three risk decile subgroups (positive predictive value: 6%-14%). The top 10 GBM-identified predictors included albumin, liver enzymes (aspartate aminotransferase, alkaline phosphatase), total bilirubin levels, sex, HCV viral loads, sodium level, HCC, platelet levels, and tobacco use. CONCLUSIONS: Machine learning algorithms performed effectively for risk prediction and stratification of DAA treatment failure.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Park H, Lo-Ciganic WH, Huang J, et al. Machine learning algorithms for predicting direct-acting antiviral treatment failure in chronic hepatitis C: An HCV-TARGET analysis. Hepatology. 2022. PMID: 35034373. doi:10.1002/hep.32347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。